From Research at med.fsu.edu Fri Jul 17 14:45:46 2020 From: Research at med.fsu.edu (Med Research) Date: Fri, 17 Jul 2020 18:45:46 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16F25AC@FSUCOM128.med.ad.fsu.edu> Florida Department of Health Biomedical Research Grant Programs (please notify Med-RA if you intend to submit a letter of intent for these programs) William G. "Bill" Bankhead, Jr., and David Coley Cancer Research Program Priority will be given to applications that address at least one of the following: lung cancer, breast cancer, prostate cancer, colon cancer, or melanoma. To balance the number of grants awarded across Research Priorities, this year the Department will further prioritize applications that address the following: 1. Reduction of mortality and morbidity as related to health disparities. 2. Improve screening accuracy and detection in high risk groups. 3. Resistance to front-line treatments in recurrent disease in the five cancers listed. 4. Research focused on sarcomas, or leukemia and other blood cancers. 5. Examine the relationship between obesity and cancer, cancer treatment responsiveness, and cancer treatment-related morbidities. Required letter of intent due July 29, 2020. Application due September 16, 2020. Med-RA deadline to receive application draft documents: September 2. James and Esther King Biomedical Research Program The purpose of the program is to support research initiatives that address the health care problems of Floridians in the areas of tobacco-related cancer, cardiovascular disease, stroke, and pulmonary disease. In order to balance the number of grants awarded across Research Priorities, this year the Department will prioritize applications that address the following: 1. Reduction of mortality and morbidity as related to health disparities. 2. Improve screening accuracy and detection in high risk groups. 3. Prevention and treatment research evaluating programs for tobacco use reduction and prevention. 4. Prevention of the transition from electronic nicotine to combustible tobacco usage, or demonstrates the effectiveness of the use of electronic nicotine in the reduction or elimination of the use of combustible tobacco. Required letter of intent due July 29, 2020. Application due September 16, 2020. Med-RA deadline to receive application draft documents: September 2. Live Like Bella Pediatric Cancer Research Initiative This FOA covers cancers that occur during the pediatric period, from birth to 21 years, and will provide grants for research to further the search for cures for pediatric cancer, by pursuing the following goals: 1. Significantly expand pediatric cancer research capacity in Florida. 2. Improve both research and treatment through greater pediatric enrollment in clinical trials networks. 3. Reduce the impact of pediatric cancer on disparate groups. Required letter of intent due July 29, 2020. Application due September 16, 2020. Med-RA deadline to receive application draft documents: September 2. Ed and Ethel Moore Alzheimer's Disease Research Program The purpose of the Program is to fund research leading to prevention of, or a cure for, Alzheimer?s disease by pursuing the following goals: 1. Improve the health of Floridians by researching better prevention and diagnoses of, and treatments and cures for, Alzheimer?s disease. 2. Expand the foundation of knowledge relating to the prevention, diagnosis, treatment, and cure of Alzheimer?s disease. 3. Stimulate economic activity in Florida in areas related to Alzheimer?s disease research. High priority will be given to biomedical or behavioral clinical trial recruitment and participation in observational or experimental research studies that involve special populations and underserved areas. Required letter of intent due July 31, 2020. Application due September 9, 2020. Med-RA deadline to receive application draft documents: August 26. Congressionally Directed Medical Research Programs Pancreatic Cancer Research Program Idea Development Award Pre-application (preproposal): August 25, 2020. Application: November 2, 2020. Translational Research Award Pre-application (preproposal): August 25, 2020. Application: November 2, 2020. Med-RA deadline to receive draft application documents: October 20. Reconstructive Transplant Research Program Investigator Initiated Research Award Pre-application (preproposal): August 19, 2020. Application: November 12, 2020. Med-RA deadline to receive draft application documents: October 29. Charles Koch Foundation: Substance Abuse Research Grants The Charles Koch Foundation seeks to support research projects (e.g. papers, conferences, workshops, etc.) that explore innovative, community-based solutions that are targeted at destroying the root causes of substance abuse. To that end, we are actively soliciting proposals for projects to consider innovative solutions that seek to alleviate substance use disorders. We are especially interested in research that: * Addresses innovative ways to help individuals overcome substance use disorders, prevent drug overdoses, and increase the willingness of individuals to seek treatment for substance abuse. * Explores the root causes of addiction and substance use disorders as well as innovative means to prevent substance abuse by remedying these root causes. * Addresses the unintended consequences of current approaches to reduce drug overdoses and substance abuse. * Examines solutions that offer a proactive approach to fighting addiction rather than a reactive approach focusing on treatment and recovery. * Explores opportunities to reduce the stigma associated with substance use disorders and celebrate success in overcoming addiction and substance abuse. Funding levels are commensurate with the requirements of the research and the potential for the research to advance an understanding of critical issues. Accepted proposals may also receive support to disseminate the research findings. Applications accepted on a rolling basis. Med-RA deadline to receive draft documents: Ten business days before submission. BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed) This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new noninvasive imaging methods or unusually bold approaches for existing noninvasive imaging methods that will lead to transformative advances in our understanding of the function and connectivity of the human brain. The FOA solicits small-scale projects to prove exceptionally innovative, original and/or unconventional concepts. Due September 3, 2020 and September 3, 2021. Med-RA deadline to receive draft documents for September 3, 2020 due date: August 24. BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01 Clinical Trial Not Allowed) This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support full development of entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. The FOA seeks innovative applications that are ready for full-scale development of breakthrough technologies with the intention of delivering working tools. Due September 3, 2020 and September 3, 2021. Med-RA deadline to receive draft documents for September 3, 2020 due date: August 24. BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) This FOA solicits the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to either support or refute a stated hypothesis about brain function. It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification. Investigative studies should be limited to model parameter estimation and/or validity testing of the tools being developed. Due September 14, 2020. Med-RA deadline to receive draft documents: August 31. NICHD Research Education Programs (R25 Clinical Trial Not Allowed) This FOA invites applications to develop and conduct short-term research education programs to improve the knowledge and research skills of biomedical and behavioral scientists conducting research in areas relevant to the mission of NICHD, including reproductive, developmental, behavioral, social, and rehabilitative processes that determine the health and well-being of newborns, infants, children, adults, families, and populations. Programs must be unique and provide compelling value to students and/or investigators in the field. Depending on the goals of the proposed training programs, the duration of the short courses can vary from one week or less to a maximum of 12 weeks. Recurring courses are allowed. R25 programs may be proposed in any research area relevant to the mission of NICHD. Areas of particular interest include: 1. Training in specialized research techniques, research methodology, data sets, or statistical approaches. 2. Training in advanced approaches to clinical, translational, or basic research, for instance, training in design and implementation of clinical trials or complex data collection projects. 3. Training in the use of model organisms or systems. 4. Short-term courses to expose upper undergraduates in the scientific areas that are within the scientific scope of the NICHD. 5. Specialized training on data sharing that addresses issues such as disclosure review, discoverability, multi-site access to restricted-access data, interoperability, and other aspects of ensuring confidentiality and maximizing data accessibility. 6. Computational analysis of genomic data to identify genomic variants associated with structural birth defects. 7. Gene editing techniques for producing organisms modeling structural birth defects or studying genes involved with embryonic development. 8. Approaches toward analyzing and modeling developmental gene regulatory networks. 9. Collection of phenotypic and clinical data using controlled vocabularies and ontologies for standardized phenotyping of structural birth defects. Standard dates apply. Expires May 26, 2022. Med-RA deadline to receive draft documents for September 25 standard date: September 11. Cigna Healthier Kids for Our Future: Food Insecurity and Mental Health Grants Food Insecurity We want to work with organizations that are on the ground, in the communities, working to address food security throughout the world. We have learned that schools?at least in the U.S. and in many countries?are a focal point for addressing this issue and in most cases, already have programs supporting at-risk populations. With that in mind, we want to fill the gaps that exist in and outside the school environment. We are looking for programs that attempt to address these, and other gaps, in delivering food and nutritional education to children. The Cigna Foundation is looking for programs that bracket or augment in-school efforts in the following areas: 1. Community-based programs that support children and families? access to healthy meals and nutritional education outside the school setting, on weekends and during the summer 2. Food and nutritional programs that provide support for expecting mothers and caregivers 3. Support for programs that address the needs of pre-school children 4. Health provider/clinician efforts that provide nutritional education to patients and/or food as prescription programming 5. School-based programs that enhance or augment state and/or federal assistance efforts Mental Health Our goal is to supplement existing mental health programming, and help close gaps both within and outside the school environment to address loneliness, anxiety, depression, and suicide prevention. We will fund programs that foster collaboration between stakeholders including school administrators and teachers, clinicians, and local and national nonprofits to address mental health and emotional well-being challenges for children. Partners are encouraged to leverage one or more of the follow evidence-based programs: * Trauma Informed Practices (TIPS) * Social Emotional Learning (SEL) * Positive Behavioral Interventions and Supports (PBIS) Both are due September 30, 2020. Med-RA deadline to receive draft documents: September 17. Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s) of COAs and their related endpoints for specific disease indications or for disease impacts that span multiple rare diseases of similar phenotypes. The UG3/UH3 Phase Innovation Award Cooperative Agreement involves 2 phases. The UG3 phase will provide funding for 1 to 2 years to conduct planning activities. The UH3 phase will provide funding for 3 to 4 years to projects that successfully complete the planning activities and reach the projected milestones set in the UG3 phase. UH3 phase awards will be awarded after administrative review of eligible UG3 phase awards that have met the scientific milestone and feasibility requirements necessary for UH3 phase implementation. The number of awards is dependent on the availability of funds. The UG3/UH3 application must be submitted as a single application, and applicants should note specific instructions for each phase in this FOA. The total award project period will not exceed 5 years. Due October 14, 2020. Med-RA deadline to receive draft documents: October 1. Aging, Cancer-Initiating Cells, and Cancer Development (U01 Clinical Trial Not Allowed) Through this Funding Opportunity Announcement, the National Cancer Institute and National Institute on Aging will promote research to advance the understanding of the mechanistic factors and cellular interactions during aging that contribute to cancer initiation. Collaborations are strongly encouraged between scientists in the fields of aging biology and cancer biology. Applications should address key questions regarding how hallmarks of aging that lead to impaired cellular activities (metabolic alterations, proteostasis, epigenetic changes, and DNA repair) and alterations in the microenvironment (inflammation and immunosenescence) contribute to the development and outgrowth of cancer-initiating cells. Due October 27, 2020 and February 17, 2021. Med-RA deadline to receive draft documents for October 27, 2020 due date: October 14. Alkermes Pathways Research Awards Program This program will support projects focused on substance use disorders (SUDs), schizophrenia and bipolar disorder. Open to early career investigators committed to advancing research in SUDs, schizophrenia or bipolar disorder, the Pathways program provides individual grant amounts of up to $100,000 per project in research focusing on SUD, schizophrenia or bipolar disorder. Areas of Interest * Preclinical, clinical, translational and epidemiological research * Research on treatment and patient centered outcomes * Clinical and health economic outcomes using real-world data * Outcomes research supporting continuity of care utilizing telehealth or other technology-based approaches Open to Assistant Professors who have not been awarded an R01 or equivalent. Due October 30, 2020. Med-RA deadline to receive draft documents: October 19. PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional) NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users. This RFA is restricted to projects conducted in the United States, although foreign components are permitted where they support domestic research in the United States. Applications are encouraged that propose research in states and counties identified in the US Government?s Ending the HIV Epidemic (EtHE) initiative as described here: Ending the HIV Epidemic: A Plan for America https://urldefense.com/v3/__https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview__;!!PhOWcWs!gOmOX9Ujd6mpGirI3MEFvC33zWCU1Eh-OQDMOp3Uh2Ri3lu15QP484tUJBMvly-vhrOaOl-hySudq6GGPzM$ . Applications to work in locales that are not included in the EtHE initiative must provide an epidemiologic justification for their inclusion in the research. Due November 12, 2020. Med-RA deadline to receive draft documents: October 29. Using Human Cell Animal Chimera Brains to Study HIV Latency and Pathology R01 ? Clinical Trials Not Allowed This Funding Opportunity Announcement invites applications for pre-clinical and translational research using human cell-mice chimera animals to study HIV pathology in functional live brain environments, with the presence of abused substances. Research awards are expected to support replicable mechanistic studies that enable the advancement of translational development for the interventions and treatments of HIV-associated neurological disorders and for the eventual eradication of HIV from brain cells containing HIV provirus. Due November 13, 2020. Med-RA deadline to receive draft documents: November 2. Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 ? Clinical Trial Optional) This Funding Opportunity Announcement aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations. August 20, 2020; December 2, 2020; and March 2, 2021. Med-RA deadline to receive draft documents for August 20, 2020 due date: August 10. Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases. Due December 16, 2020. Med-RA deadline to receive draft documents: December 3. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: